Literature DB >> 18671706

High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis.

M Dungarwalla1, S Appiah-Cubi, S Kulkarni, R Saso, A Wotherspoon, N Osuji, J Swansbury, D C Cunningham, D Catovsky, C E Dearden, E Matutes.   

Abstract

In a series of 48 patients with splenic marginal zone lymphoma (SMZL) with circulating villous lymphocytes, we describe the clinical and laboratory features of nine cases that transformed to high-grade B-cell lymphoma. These patients had a significantly greater incidence of peripheral lymph node involvement at diagnosis when compared to SMZL patients who did not transform (P < 0.03). While transformation in the bone marrow is frequently refractory to therapy and associated with poor outcome in SMZL, lymph node transformation responds well to chemotherapy with durable progression-free and overall survival.

Entities:  

Mesh:

Year:  2008        PMID: 18671706     DOI: 10.1111/j.1365-2141.2008.07301.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Splenic marginal zone lymphoma: hydra with many heads?

Authors:  Luca Arcaini; Marco Paulli
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

2.  Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

Authors:  Luca Arcaini; Davide Rossi
Journal:  Haematologica       Date:  2012-05       Impact factor: 9.941

3.  Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma.

Authors:  Rajko Milosevic; Milena Todorovic; Bela Balint; Miodrag Jevtic; Miodrag Krstic; Elizabeta Ristanovic; Nebojsa Antonijevic; Mirjana Pavlovic; Maja Perunicic; Milan Petrovic; Biljana Mihaljevic
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

4.  A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation.

Authors:  Xiaofeng Shi; Rong Ba; Haiyan You; Qian Jiang; Jiansong Huang; Jianhua Mao; Lanxiu Han; Shuo Zhang; Qin Zhuang; Xianqiu Yu; Lixia Wang; Yun Wang; Dongya Li; Wei Zhu; Yong Zhang; Yan Zhu; Xiaodong Xi
Journal:  Front Med       Date:  2017-10-27       Impact factor: 4.592

5.  Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.

Authors:  Gabriela Bastidas-Mora; Sílvia Beà; Alba Navarro; Eva Gine; Dolors Costa; Julio Delgado; Tycho Baumann; Laura Magnano; Alfredo Rivas-Delgado; Neus Villamor; Dolors Colomer; Mónica Lopez-Guerra; María Rozman; Olga Balagué; Daniel Martínez; Maria Joao Baptista; Lourdes Escoda; Miguel Alcoceba; Margarita Blanes; Fina Climent; Elías Campo; Andrew Wotherspoon; Armando López-Guillermo; Estella Matutes
Journal:  Br J Haematol       Date:  2021-09-14       Impact factor: 8.615

6.  Highlights of 2008 in bone marrow biopsy pathology.

Authors:  Jon van der Walt
Journal:  J Hematop       Date:  2009-02-24       Impact factor: 0.196

7.  Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma.

Authors:  Aniko Fodor; Miklos Zsolt Molnar; Laszlo Krenacs; Eniko Bagdi; Judit Csomor; Andras Matolcsy; Judit Demeter
Journal:  Pathol Oncol Res       Date:  2009-04-03       Impact factor: 3.201

8.  Clinical characteristics and outcome in dogs with splenic marginal zone lymphoma.

Authors:  D O'Brien; P F Moore; W Vernau; J R Peauroi; R B Rebhun; C O Rodriguez; K A Skorupski
Journal:  J Vet Intern Med       Date:  2013-06-04       Impact factor: 3.333

9.  Unusual Course of Splenic Marginal Zone Lymphoma.

Authors:  Nay T Tun; Kaihong Mi; John Smith
Journal:  World J Oncol       Date:  2013-09-27

10.  Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.

Authors:  Jan Peveling-Oberhag; Franziska Wolters; Claudia Döring; Dirk Walter; Ludger Sellmann; René Scholtysik; Marco Lucioni; Max Schubach; Marco Paulli; Saskia Biskup; Stefan Zeuzem; Ralf Küppers; Martin-Leo Hansmann
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.